mcc tool Search Results


rapidlasso lastools  (Rapidlasso GmbH)
90
Rapidlasso GmbH rapidlasso lastools
Rapidlasso Lastools, supplied by Rapidlasso GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rapidlasso lastools/product/Rapidlasso GmbH
Average 90 stars, based on 1 article reviews
rapidlasso lastools - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
nlrp3 inhibitor tool compound mcc 950  (Selleck Chemicals)
95
Selleck Chemicals nlrp3 inhibitor tool compound mcc 950
Human microglial pathways not impacted by fenebrutinib treatment. A Cytokine and chemokine release from LPS-stimulated (0.1 μg/mL) human iMicroglia incubated with fenebrutinib or ibrutinib (both 1 μM) for 24 h. While BTK inhibition reduced levels of GM-CSF and CCL17, limited effects were observed for other cytokines and chemokines that are increased with LPS stimulation. B IL-1β release from human iMicroglia incubated with fenebrutinib or MCC-950 (0.01–1 μM) and stimulated with LPS (0.1 μg/mL; 3 h) followed by nigericin (10 μM; 1 h). Fenebrutinib had no effect on IL-1β release in contrast to MCC-950, which dose dependently reduced IL-1β levels. C Phagocytosis of pHrodo-conjugated myelin by human iMicroglia incubated with fenebrutinib or ibrutinib (0.01–1 μM) for 24 h. Fenebrutinib had no effect on myelin phagocytosis, while ibrutinib reduced myelin phagocytosis at 1 μM only. Data are shown as mean ± SD; individual dots represent replicate wells. Results are representative of two to three independent experiments. Significance is indicated by **** P < 0.0001, *** P < 0.001 and * P < 0.05, determined by one‐way ANOVA and Tukey’s post hoc test. ANOVA analysis of variance, BTK Bruton’s tyrosine kinase, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemokine ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, FEN fenebrutinib, IL interleukin, iMicroglia induced pluripotent stem cell-derived microglia, LPS lipopolysaccharide, <t>NLRP3</t> NACHT, LRR and PYD domains-containing protein 3, SD standard deviation, TNF tumor necrosis factor
Nlrp3 Inhibitor Tool Compound Mcc 950, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nlrp3 inhibitor tool compound mcc 950/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
nlrp3 inhibitor tool compound mcc 950 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
matthews correlation coefficient (mcc) calculator  (MedCalc Software Ltd)
90
MedCalc Software Ltd matthews correlation coefficient (mcc) calculator
Human microglial pathways not impacted by fenebrutinib treatment. A Cytokine and chemokine release from LPS-stimulated (0.1 μg/mL) human iMicroglia incubated with fenebrutinib or ibrutinib (both 1 μM) for 24 h. While BTK inhibition reduced levels of GM-CSF and CCL17, limited effects were observed for other cytokines and chemokines that are increased with LPS stimulation. B IL-1β release from human iMicroglia incubated with fenebrutinib or MCC-950 (0.01–1 μM) and stimulated with LPS (0.1 μg/mL; 3 h) followed by nigericin (10 μM; 1 h). Fenebrutinib had no effect on IL-1β release in contrast to MCC-950, which dose dependently reduced IL-1β levels. C Phagocytosis of pHrodo-conjugated myelin by human iMicroglia incubated with fenebrutinib or ibrutinib (0.01–1 μM) for 24 h. Fenebrutinib had no effect on myelin phagocytosis, while ibrutinib reduced myelin phagocytosis at 1 μM only. Data are shown as mean ± SD; individual dots represent replicate wells. Results are representative of two to three independent experiments. Significance is indicated by **** P < 0.0001, *** P < 0.001 and * P < 0.05, determined by one‐way ANOVA and Tukey’s post hoc test. ANOVA analysis of variance, BTK Bruton’s tyrosine kinase, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemokine ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, FEN fenebrutinib, IL interleukin, iMicroglia induced pluripotent stem cell-derived microglia, LPS lipopolysaccharide, <t>NLRP3</t> NACHT, LRR and PYD domains-containing protein 3, SD standard deviation, TNF tumor necrosis factor
Matthews Correlation Coefficient (Mcc) Calculator, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/matthews correlation coefficient (mcc) calculator/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
matthews correlation coefficient (mcc) calculator - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mcc software  (Peau Productions Inc)
90
Peau Productions Inc mcc software
Human microglial pathways not impacted by fenebrutinib treatment. A Cytokine and chemokine release from LPS-stimulated (0.1 μg/mL) human iMicroglia incubated with fenebrutinib or ibrutinib (both 1 μM) for 24 h. While BTK inhibition reduced levels of GM-CSF and CCL17, limited effects were observed for other cytokines and chemokines that are increased with LPS stimulation. B IL-1β release from human iMicroglia incubated with fenebrutinib or MCC-950 (0.01–1 μM) and stimulated with LPS (0.1 μg/mL; 3 h) followed by nigericin (10 μM; 1 h). Fenebrutinib had no effect on IL-1β release in contrast to MCC-950, which dose dependently reduced IL-1β levels. C Phagocytosis of pHrodo-conjugated myelin by human iMicroglia incubated with fenebrutinib or ibrutinib (0.01–1 μM) for 24 h. Fenebrutinib had no effect on myelin phagocytosis, while ibrutinib reduced myelin phagocytosis at 1 μM only. Data are shown as mean ± SD; individual dots represent replicate wells. Results are representative of two to three independent experiments. Significance is indicated by **** P < 0.0001, *** P < 0.001 and * P < 0.05, determined by one‐way ANOVA and Tukey’s post hoc test. ANOVA analysis of variance, BTK Bruton’s tyrosine kinase, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemokine ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, FEN fenebrutinib, IL interleukin, iMicroglia induced pluripotent stem cell-derived microglia, LPS lipopolysaccharide, <t>NLRP3</t> NACHT, LRR and PYD domains-containing protein 3, SD standard deviation, TNF tumor necrosis factor
Mcc Software, supplied by Peau Productions Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mcc software/product/Peau Productions Inc
Average 90 stars, based on 1 article reviews
mcc software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
3.3 mcc software  (DeltaSoft Inc)
90
DeltaSoft Inc 3.3 mcc software
Human microglial pathways not impacted by fenebrutinib treatment. A Cytokine and chemokine release from LPS-stimulated (0.1 μg/mL) human iMicroglia incubated with fenebrutinib or ibrutinib (both 1 μM) for 24 h. While BTK inhibition reduced levels of GM-CSF and CCL17, limited effects were observed for other cytokines and chemokines that are increased with LPS stimulation. B IL-1β release from human iMicroglia incubated with fenebrutinib or MCC-950 (0.01–1 μM) and stimulated with LPS (0.1 μg/mL; 3 h) followed by nigericin (10 μM; 1 h). Fenebrutinib had no effect on IL-1β release in contrast to MCC-950, which dose dependently reduced IL-1β levels. C Phagocytosis of pHrodo-conjugated myelin by human iMicroglia incubated with fenebrutinib or ibrutinib (0.01–1 μM) for 24 h. Fenebrutinib had no effect on myelin phagocytosis, while ibrutinib reduced myelin phagocytosis at 1 μM only. Data are shown as mean ± SD; individual dots represent replicate wells. Results are representative of two to three independent experiments. Significance is indicated by **** P < 0.0001, *** P < 0.001 and * P < 0.05, determined by one‐way ANOVA and Tukey’s post hoc test. ANOVA analysis of variance, BTK Bruton’s tyrosine kinase, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemokine ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, FEN fenebrutinib, IL interleukin, iMicroglia induced pluripotent stem cell-derived microglia, LPS lipopolysaccharide, <t>NLRP3</t> NACHT, LRR and PYD domains-containing protein 3, SD standard deviation, TNF tumor necrosis factor
3.3 Mcc Software, supplied by DeltaSoft Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3.3 mcc software/product/DeltaSoft Inc
Average 90 stars, based on 1 article reviews
3.3 mcc software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mcc950 sodium  (Enamine Ltd)
N/A
MCC950 sodium is a potent, selective NLRP3 inhibitor. MCC950 sodium salt shows analgesic agent effect.
   Buy from Supplier

Image Search Results


Human microglial pathways not impacted by fenebrutinib treatment. A Cytokine and chemokine release from LPS-stimulated (0.1 μg/mL) human iMicroglia incubated with fenebrutinib or ibrutinib (both 1 μM) for 24 h. While BTK inhibition reduced levels of GM-CSF and CCL17, limited effects were observed for other cytokines and chemokines that are increased with LPS stimulation. B IL-1β release from human iMicroglia incubated with fenebrutinib or MCC-950 (0.01–1 μM) and stimulated with LPS (0.1 μg/mL; 3 h) followed by nigericin (10 μM; 1 h). Fenebrutinib had no effect on IL-1β release in contrast to MCC-950, which dose dependently reduced IL-1β levels. C Phagocytosis of pHrodo-conjugated myelin by human iMicroglia incubated with fenebrutinib or ibrutinib (0.01–1 μM) for 24 h. Fenebrutinib had no effect on myelin phagocytosis, while ibrutinib reduced myelin phagocytosis at 1 μM only. Data are shown as mean ± SD; individual dots represent replicate wells. Results are representative of two to three independent experiments. Significance is indicated by **** P < 0.0001, *** P < 0.001 and * P < 0.05, determined by one‐way ANOVA and Tukey’s post hoc test. ANOVA analysis of variance, BTK Bruton’s tyrosine kinase, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemokine ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, FEN fenebrutinib, IL interleukin, iMicroglia induced pluripotent stem cell-derived microglia, LPS lipopolysaccharide, NLRP3 NACHT, LRR and PYD domains-containing protein 3, SD standard deviation, TNF tumor necrosis factor

Journal: Journal of Neuroinflammation

Article Title: Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways

doi: 10.1186/s12974-024-03267-5

Figure Lengend Snippet: Human microglial pathways not impacted by fenebrutinib treatment. A Cytokine and chemokine release from LPS-stimulated (0.1 μg/mL) human iMicroglia incubated with fenebrutinib or ibrutinib (both 1 μM) for 24 h. While BTK inhibition reduced levels of GM-CSF and CCL17, limited effects were observed for other cytokines and chemokines that are increased with LPS stimulation. B IL-1β release from human iMicroglia incubated with fenebrutinib or MCC-950 (0.01–1 μM) and stimulated with LPS (0.1 μg/mL; 3 h) followed by nigericin (10 μM; 1 h). Fenebrutinib had no effect on IL-1β release in contrast to MCC-950, which dose dependently reduced IL-1β levels. C Phagocytosis of pHrodo-conjugated myelin by human iMicroglia incubated with fenebrutinib or ibrutinib (0.01–1 μM) for 24 h. Fenebrutinib had no effect on myelin phagocytosis, while ibrutinib reduced myelin phagocytosis at 1 μM only. Data are shown as mean ± SD; individual dots represent replicate wells. Results are representative of two to three independent experiments. Significance is indicated by **** P < 0.0001, *** P < 0.001 and * P < 0.05, determined by one‐way ANOVA and Tukey’s post hoc test. ANOVA analysis of variance, BTK Bruton’s tyrosine kinase, CCL C-C motif chemokine ligand, CXCL C-X-C motif chemokine ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, FEN fenebrutinib, IL interleukin, iMicroglia induced pluripotent stem cell-derived microglia, LPS lipopolysaccharide, NLRP3 NACHT, LRR and PYD domains-containing protein 3, SD standard deviation, TNF tumor necrosis factor

Article Snippet: Cells were stimulated with lipopolysaccharide (LPS from E. coli, Serotype O55:B5, Enzo Life Sciences, ALX-581-013; 1 μg/mL) for 3 h. NLRP3 inhibitor tool compound MCC-950 (CP-456773 sodium salt; Selleckchem, S7809; 0.01–1 μM), fenebrutinib (0.01–1 μM) or vehicle (DMSO; Sigma, D2650) were added prior to nigericin (10 μM; Invivogen, tlrl-nig-5) addition.

Techniques: Incubation, Inhibition, Derivative Assay, Standard Deviation